Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2020-09-09 Capital/Financing Update
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
Other.pdf
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under a registration statement with the SEC. It details an offering of 8,500,000 common shares, including underwriting details, listing information, risk factors, use of proceeds, and other offering-specific disclosures. The text includes disclaimers about the offer not being complete and not an offer to sell in certain jurisdictions. This type of document is a capital raising filing related to a securities offering, specifically a prospectus supplement which updates and adds to a base prospectus. It is not a financial report, earnings release, management discussion, or any other report type. It is clearly a Capital/Financing Update as it relates to a new share offering and associated financing activities.
2020-09-09 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a proposed public offering of common shares by Trillium Therapeutics Inc. It details the number of shares to be offered, the intended use of proceeds, underwriters involved, regulatory approvals required, and references to the SEC registration statement and prospectus supplement. There are no financial statements or detailed financial performance data presented. The content focuses on capital raising activities and financing terms, which aligns with a Capital/Financing Update. The document length is about 6000 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-09-09 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Securities Purchase Agreement' and details the terms and conditions of a share purchase transaction between Trillium Therapeutics Inc. and Pfizer Inc. It includes definitions, purchase and sale terms, closing conditions, and representations and warranties. The content is a legal contract related to a capital raising transaction involving the issuance and sale of common shares. There is no indication that this is a financial report, earnings release, or regulatory filing of financial results. Instead, it is a detailed agreement documenting a financing transaction. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed contractual content support this classification with high confidence.
2020-09-09 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is titled as a "Prospectus Supplement" filed pursuant to Rule 424(b)(5) and includes detailed information about an offering of common shares, including the number of shares, price, use of proceeds, risk factors, and legal considerations. It references a shelf registration statement and provides detailed terms of the securities offering. This type of document is a formal offering prospectus supplement related to capital raising activities. It is not an annual or quarterly report, earnings release, or management discussion. It is specifically related to a financing event and the issuance of new shares. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual prospectus supplement, not just an announcement of a report. Hence, the classification is CAP with high confidence.
2020-09-09 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a $25 million equity investment by Pfizer Inc. in Trillium Therapeutics. It details the terms of the transaction, the number of shares sold, the price per share, and the intended use of proceeds. It also mentions the appointment of a Pfizer executive to Trillium's Scientific Advisory Board. There is no financial report, earnings data, or detailed financial statements included. The document is focused on a capital raising event and related corporate update. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 5726 characters, which is sufficient for a detailed announcement but does not contain financial statements or analysis that would classify it as an Interim Report or Annual Report. Hence, the classification is CAP with high confidence.
2020-09-08 English
News release - English.pdf
Earnings Release Classification · 90% confidence The document is a press release announcing updated clinical data from ongoing dose escalation studies of Trillium Therapeutics' drug candidates TTI-622 and TTI-621. It includes detailed clinical trial results, safety assessments, and response rates. The document also announces a conference call to discuss the data. There is no indication that this is a full financial report, audit report, or regulatory filing. It is not an earnings release since it focuses on clinical trial data rather than financial results. The presence of a conference call announcement suggests this is a Call Transcript or related document, but the text itself is a press release with clinical data updates rather than a transcript. The document is longer than 5,000 characters and contains substantive data, so it is not a mere announcement of a report. The best fitting category is Earnings Release (ER) because it is an initial announcement of important periodic data (clinical trial results) that can impact the company's valuation and investor decisions, and it includes a conference call announcement. Confidence is high given the detailed clinical data and the nature of the announcement. Q3 2020
2020-09-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.